Infections caused by non-tuberculous mycobacteria (NTM) are increasing globally and are
notoriously difficult to treat due to intrinsic resistance of these bacteria to many common …

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of
which can produce disease in humans of all ages and can affect both pulmonary and …

Nontuberculous mycobacteria (NTM) are emerging human pathogens, causing a wide
range of clinical diseases affecting individuals who are immunocompromised and who have …

Mycobacterium abscessus is the second most common nontuberculous mycobacterial lung
disease pathogen and comprises three subspecies: abscessus, massiliense, and bolletii …

The lung is an attractive target for drug delivery because of the ease of non-invasive
administration via inhalation, bypassing metabolism in the liver, direct delivery to the …

The management of difficult-to-treat acute and chronic respiratory infections (infections in
cystic fibrosis, non-cystic fibrosis bronchiectasis, immunocompromised and mechanically …

Liposomes have become a research hotspot in recent years as food delivery systems with
attractive properties, including the bilayer structure assembled like the cell membrane …

The exploitation of nanosized materials for the delivery of therapeutic agents is already a
clinical reality and still holds unrealized potential for the treatment of a variety of diseases …

Recommendations for first-line and second-line drug testing and organism group, specific
methodologies, and reporting recommendations have been addressed by the Clinical and …

The pathogen Mycobacterium avium complex (MAC) is the most common cause of
nontuberculous mycobacterial pulmonary disease worldwide. The decision to initiate long …